Cellular oncology (Dordrecht) : Impact Factor & More
eISSN: 2211-3436pISSN: 2211-3428
Share this on:
Key Metrics
CiteScore 
9.7
SNIP
1.27
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Cellular oncology (Dordrecht) Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1989 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Cellular oncology (Dordrecht) ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cellular oncology (Dordrecht)
EZH2 inhibition triggers a context-specific ACSS2-H3K9ac-HK2 metabolic circuit in EZH2 non-mutant solid tumors.
- 16 May 2026
- Cellular oncology (Dordrecht, Netherlands)
Machine learning-based integrative analysis identifies CXCL13-driven tertiary lymphoid structures as favorable immune and prognostic features in osteosarcoma.
- 16 May 2026
- Cellular oncology (Dordrecht, Netherlands)
CTMP-REV7 axis modulates MHC-I antigen presentation via CDK1-AKT crosstalk in MSI-L/MSS colorectal cancer.
- 16 May 2026
- Cellular oncology (Dordrecht, Netherlands)
USP10 confers lenvatinib resistance in hepatocellular carcinoma by deubiquitinating the GPX2.
- 14 May 2026
- Cellular oncology (Dordrecht, Netherlands)
Super-enhancer-associated lncRNA HDAC11-AS1 aggravates hepatocellular carcinoma progression by modulating HDAC11 and NUP210 expression via promoting super-enhancer activity.
- 13 May 2026
- Cellular oncology (Dordrecht, Netherlands)
RBM15/IGF2BP2-PTPRH m6A regulatory axis in non-small cell lung cancer.
- 11 May 2026
- Cellular oncology (Dordrecht, Netherlands)
EZH2 inhibition triggers a context-specific ACSS2-H3K9ac-HK2 metabolic circuit in EZH2 non-mutant solid tumors.
- 16 May 2026
- Cellular oncology (Dordrecht, Netherlands)
Machine learning-based integrative analysis identifies CXCL13-driven tertiary lymphoid structures as favorable immune and prognostic features in osteosarcoma.
- 16 May 2026
- Cellular oncology (Dordrecht, Netherlands)
CTMP-REV7 axis modulates MHC-I antigen presentation via CDK1-AKT crosstalk in MSI-L/MSS colorectal cancer.
- 16 May 2026
- Cellular oncology (Dordrecht, Netherlands)
USP10 confers lenvatinib resistance in hepatocellular carcinoma by deubiquitinating the GPX2.
- 14 May 2026
- Cellular oncology (Dordrecht, Netherlands)
Super-enhancer-associated lncRNA HDAC11-AS1 aggravates hepatocellular carcinoma progression by modulating HDAC11 and NUP210 expression via promoting super-enhancer activity.
- 13 May 2026
- Cellular oncology (Dordrecht, Netherlands)
RBM15/IGF2BP2-PTPRH m6A regulatory axis in non-small cell lung cancer.
- 11 May 2026
- Cellular oncology (Dordrecht, Netherlands)
FAQs on Cellular oncology (Dordrecht)
How long has Cellular oncology (Dordrecht) been actively publishing? 
What is the publishing frequency of Cellular oncology (Dordrecht)?
How many articles did Cellular oncology (Dordrecht) publish last year?
What is the eISSN & pISSN for Cellular oncology (Dordrecht)?
What is Citescore for Cellular oncology (Dordrecht)?
What is SNIP score for Cellular oncology (Dordrecht)?
Who is the publisher of Cellular oncology (Dordrecht)?
